ANIPANI PHARMACEUTICALS INC
- Market cap
- $1.67B
- as of 2026-10-23
- Latest close
- $72.61
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Drug Manufacturers - Specialty & Generic
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2023-10-03
Dashed line = amended filing (Form 4/A)
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Lalwani NikhilPRESIDENT & CEO | Oct 15 | Oct 16 | S | 5,400 | $71.89 | Sale −$388,206 | 333,689 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Oct 13 | Oct 13 | S | 500 | $73.59 | Sale −$36,795 | 73,424 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Sep 29 | Sep 30 | S | 2,850 | $73.00 | Sale −$208,050 | 168,993 | Yes | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Sep 15 | Sep 16 | S | 5,400 | $71.00 | Sale −$383,400 | 339,089 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sep 14 | Sep 14 | S | 500 | $70.79 | Sale −$35,395 | 73,924 | Yes | Form 4 |
| Thoma Jeanne | Sep 11 | Sep 14 | S | 1,000 | $71.53 | Sale −$71,530 | 26,762 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Aug 31 | Sep 1 | S | 2,850 | $72.80 | Sale −$207,480 | 171,843 | Yes | Form 4 |
| Gosebruch Henry O | Aug 19 | Aug 27 | A | 6,662 | $0.00 | $0 | 6,662 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Aug 25 | Aug 26 | S | 5,400 | $74.30 | Sale −$401,220 | 344,489 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Aug 13 | Aug 13 | S | 500 | $75.48 | Sale −$37,740 | 74,424 | Yes | Form 4 |
| Gutwerg OriSVP, GENERICS | Aug 10 | Aug 11 | S | 3,162 | $77.00 | Sale −$243,474 | 75,534 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Jul 29 | Jul 30 | S | 2,850 | $81.36 | Sale −$231,876 | 174,693 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jul 18 | Jul 21 | F | 2,466 | $79.20 | $195,307 | 74,924 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jul 13 | Jul 14 | S | 500 | $81.84 | Sale −$40,920 | 77,390 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Jul 2 | Jul 6 | M | 3,313 | $49.51 | $164,027 | 180,856 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Jul 2 | Jul 6 | S | 3,313 | $86.00 | Sale −$284,918 | 177,543 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Jul 2 | Jul 6 | M · derivative | 3,313 | $49.51 | $164,027 | 3,313 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Jun 29 | Jun 30 | S | 2,850 | $84.12 | Sale −$239,742 | 177,543 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jun 12 | Jun 15 | S | 500 | $82.03 | Sale −$41,015 | 77,890 | Yes | Form 4 |
| Haughey Thomas | Jun 8 | Jun 10 | S | 2,000 | $80.88 | Sale −$161,760 | 38,878 | Yes | Form 4 |
| Haughey Thomas | May 21 | Jun 10 | A | 4,357 | $0.00 | $0 | 40,878 | Yes | Form 4 |
| Tannenbaum Renee P | May 21 | Jun 10 | A | 4,357 | $0.00 | $0 | 29,514 | No | Form 4 |
| Pera Antonio R | May 21 | Jun 10 | A | 4,357 | $0.00 | $0 | 27,017 | No | Form 4 |
| Leonard Matthew J | May 21 | Jun 10 | A | 4,357 | $0.00 | $0 | 11,221 | No | Form 4 |
| Thoma Jeanne | May 21 | Jun 10 | A | 4,357 | $0.00 | $0 | 27,762 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Jun 5 | Jun 9 | M | 3,312 | $49.51 | $163,977 | 183,705 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Jun 5 | Jun 9 | S | 3,312 | $80.00 | Sale −$264,960 | 180,393 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Jun 5 | Jun 9 | M · derivative | 3,312 | $49.51 | $163,977 | 6,626 | Yes | Form 4 |
| Walsh Patrick D | May 13 | May 13 | S | 10,000 | $80.63 | Sale −$806,300 | 38,432 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | May 13 | May 13 | S | 500 | $78.16 | Sale −$39,080 | 78,390 | Yes | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | May 12 | May 13 | S | 459 | $79.21 | Sale −$36,357 | 38,271 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | May 12 | May 13 | S | 2,772 | $79.50 | Sale −$220,374 | 78,696 | No | Form 4 |
| Walsh Patrick D | May 11 | May 13 | S | 3,973 | $80.75 | Sale −$320,820 | 48,432 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | May 11 | May 13 | S | 55,000 | $77.57 | Sale −$4,266,350 | 349,889 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Apr 13 | Apr 13 | S | 500 | $77.95 | Sale −$38,975 | 78,890 | Yes | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Mar 13 | Mar 13 | S | 3,162 | $71.64 | Sale −$226,526 | 91,309 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Mar 13 | Mar 13 | S | 500 | $72.62 | Sale −$36,310 | 79,390 | Yes | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Mar 11 | Mar 13 | S | 4,772 | $74.91 | Sale −$357,471 | 38,730 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Mar 9 | Mar 10 | S | 3,602 | $74.18 | Sale −$267,196 | 94,471 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Mar 9 | Mar 10 | S | 5,087 | $74.13 | Sale −$377,099 | 51,946 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 7 | Mar 10 | F | 5,150 | $74.04 | $381,306 | 180,393 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Mar 7 | Mar 10 | F | 17,060 | $74.04 | $1,263,122 | 404,889 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Mar 7 | Mar 10 | F | 3,314 | $74.04 | $245,369 | 81,468 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Mar 7 | Mar 10 | F | 3,314 | $74.04 | $245,369 | 98,073 | Yes | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Mar 6 | Mar 10 | S | 2,121 | $74.22 | Sale −$157,421 | 101,387 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Mar 6 | Mar 10 | S | 1,485 | $75.00 | Sale −$111,375 | 57,033 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 5 | Mar 5 | M | 3,312 | $49.51 | $163,977 | 192,855 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 5 | Mar 5 | S | 3,312 | $75.42 | Sale −$249,791 | 189,543 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 5 | Mar 5 | S | 4,000 | $75.56 | Sale −$302,240 | 185,543 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 5 | Mar 5 | M · derivative | 3,312 | $49.51 | $163,977 | 9,938 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Mar 3 | Mar 4 | S | 2,060 | $76.50 | Sale −$157,590 | 84,782 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Mar 2 | Mar 4 | S | 417 | $74.00 | Sale −$30,858 | 103,508 | Yes | Form 4 |
| Walsh Patrick D | Mar 3 | Mar 3 | S | 6,000 | $74.23 | Sale −$445,380 | 52,405 | No | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Feb 28 | Mar 2 | F | 628 | $73.90 | $46,409 | 43,502 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 28 | Mar 2 | F | 2,773 | $73.90 | $204,925 | 189,543 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 28 | Mar 2 | F | 12,217 | $73.90 | $902,836 | 421,949 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 28 | Mar 2 | F | 2,221 | $73.90 | $164,132 | 86,842 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 28 | Mar 2 | F | 2,221 | $73.90 | $164,132 | 103,925 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 28 | Mar 2 | F | 2,221 | $73.90 | $164,132 | 74,916 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 28 | Mar 2 | F | 1,555 | $73.90 | $114,915 | 79,890 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 28 | Mar 2 | F | 1,555 | $73.90 | $114,915 | 58,518 | No | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Feb 26 | Mar 2 | A | 6,021 | $77.15 | $464,520 | 44,130 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 26 | Mar 2 | A | 22,233 | $77.15 | $1,715,276 | 192,316 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 26 | Mar 2 | A | 75,592 | $77.15 | $5,831,923 | 434,166 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 26 | Mar 2 | A | 12,969 | $77.15 | $1,000,558 | 89,063 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 26 | Mar 2 | A | 21,306 | $77.15 | $1,643,758 | 106,146 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Feb 26 | Mar 2 | A | 11,116 | $77.15 | $857,599 | 101,056 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 26 | Mar 2 | A | 11,116 | $77.15 | $857,599 | 77,137 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 26 | Mar 2 | A | 13,895 | $77.15 | $1,071,999 | 81,445 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 26 | Mar 2 | A | 10,810 | $77.15 | $833,992 | 60,073 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 20 | Feb 23 | S | 5,323 | $78.02 | Sale −$415,300 | 84,840 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 20 | Feb 23 | S | 1,730 | $77.99 | Sale −$134,923 | 49,263 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 19 | Feb 23 | S | 2,084 | $77.53 | Sale −$161,573 | 50,993 | Yes | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Feb 14 | Feb 17 | F | 485 | $77.36 | $37,520 | 38,109 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 14 | Feb 17 | F | 2,448 | $77.36 | $189,377 | 170,083 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 14 | Feb 17 | F | 10,298 | $77.36 | $796,653 | 358,574 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 14 | Feb 17 | F | 1,888 | $77.36 | $146,056 | 76,094 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 14 | Feb 17 | F | 2,403 | $77.36 | $185,896 | 90,163 | Yes | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 14 | Feb 17 | F | 1,717 | $77.36 | $132,827 | 66,021 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 14 | Feb 17 | F | 1,779 | $77.36 | $137,623 | 67,550 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 14 | Feb 17 | F | 1,290 | $77.36 | $99,794 | 53,077 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 13 | Feb 17 | S | 500 | $76.80 | Sale −$38,400 | 69,329 | Yes | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Feb 12 | Feb 17 | F | 566 | $76.70 | $43,412 | 38,594 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 12 | Feb 17 | F | 2,829 | $76.70 | $216,984 | 172,531 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 12 | Feb 17 | F | 11,688 | $76.70 | $896,470 | 368,872 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 12 | Feb 17 | F | 1,775 | $76.70 | $136,143 | 77,982 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 12 | Feb 17 | F | 3,173 | $76.70 | $243,369 | 99,598 | Yes | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 12 | Feb 17 | S | 7,032 | $76.55 | Sale −$538,300 | 92,566 | Yes | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 12 | Feb 17 | F | 1,608 | $76.70 | $123,334 | 67,738 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 12 | Feb 17 | F | 1,534 | $76.70 | $117,658 | 69,829 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 12 | Feb 17 | F | 1,180 | $76.70 | $90,506 | 54,367 | No | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Feb 11 | Feb 13 | F | 1,762 | $76.25 | $134,353 | 39,160 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 11 | Feb 13 | F | 5,503 | $76.25 | $419,604 | 175,360 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 11 | Feb 13 | F | 30,659 | $76.25 | $2,337,749 | 380,560 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 11 | Feb 13 | F | 4,267 | $76.25 | $325,359 | 79,757 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 11 | Feb 13 | F | 4,546 | $76.25 | $346,633 | 102,771 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Feb 11 | Feb 13 | F | 2,898 | $76.25 | $220,973 | 89,940 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 11 | Feb 13 | F | 4,269 | $76.25 | $325,511 | 69,346 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 11 | Feb 13 | F | 3,011 | $76.25 | $229,589 | 71,363 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 11 | Feb 13 | F | 3,017 | $76.25 | $230,046 | 55,547 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jan 13 | Jan 14 | S | 500 | $84.33 | Sale −$42,165 | 74,374 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Dec 18, 2025 | Dec 19, 2025 | S | 1,622 | $82.40 | Sale −$133,653 | 58,564 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Dec 12, 2025 | Dec 12, 2025 | S | 400 | $82.32 | Sale −$32,928 | 74,874 | Yes | Form 4 |
| Tannenbaum Renee P | Dec 5, 2025 | Dec 9, 2025 | S | 1,800 | $81.15 | Sale −$146,070 | 25,157 | No | Form 4 |
| Walsh Patrick D | Nov 13, 2025 | Nov 17, 2025 | S | 8,643 | $86.88 | Sale −$750,904 | 61,405 | No | Form 4 |
| Walsh Patrick D | Nov 13, 2025 | Nov 17, 2025 | G | 3,000 | $0.00 | $0 | 58,405 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Nov 13, 2025 | Nov 14, 2025 | S | 94 | $88.00 | Sale −$8,272 | 158,490 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Nov 13, 2025 | Nov 14, 2025 | S | 400 | $87.27 | Sale −$34,908 | 75,274 | Yes | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Nov 12, 2025 | Nov 14, 2025 | S | 14,642 | $89.07 | Sale −$1,304,163 | 158,584 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Oct 13, 2025 | Oct 14, 2025 | S | 400 | $90.09 | Sale −$36,036 | 75,674 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Sep 19, 2025 | Sep 22, 2025 | S | 1,000 | $98.04 | Sale −$98,040 | 60,186 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sep 12, 2025 | Sep 15, 2025 | S | 400 | $98.42 | Sale −$39,368 | 76,074 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Sep 12, 2025 | Sep 15, 2025 | F | 1,710 | $97.71 | $167,084 | 61,186 | No | Form 4 |
| Pera Antonio R | Sep 3, 2025 | Sep 4, 2025 | S | 7,292 | $94.94 | Sale −$692,302 | 22,660 | No | Form 4 |
| Leonard Matthew J | Aug 25, 2025 | Aug 26, 2025 | S | 2,528 | $90.62 | Sale −$229,087 | 6,864 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Aug 22, 2025 | Aug 25, 2025 | S | 1,763 | $91.10 | Sale −$160,609 | 62,896 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Aug 21, 2025 | Aug 22, 2025 | S | 52,988 | $90.44 | Sale −$4,792,235 | 431,920 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Aug 20, 2025 | Aug 22, 2025 | S | 47,012 | $90.27 | Sale −$4,243,773 | 484,908 | No | Form 4 |
| Pera Antonio R | Aug 20, 2025 | Aug 20, 2025 | S | 5,421 | $89.73 | Sale −$486,426 | 29,952 | No | Form 4 |
| Thoma Jeanne | Aug 18, 2025 | Aug 20, 2025 | S | 6,865 | $89.76 | Sale −$616,202 | 38,080 | No | Form 4 |
| Thoma Jeanne | Aug 18, 2025 | Aug 20, 2025 | S | 14,675 | $88.87 | Sale −$1,304,167 | 23,405 | No | Form 4 |
| Leonard Matthew J | Aug 18, 2025 | Aug 18, 2025 | S | 6,937 | $88.17 | Sale −$611,635 | 9,392 | No | Form 4 |
| Walsh Patrick D | Aug 15, 2025 | Aug 18, 2025 | S | 9,000 | $89.05 | Sale −$801,450 | 70,048 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Aug 15, 2025 | Aug 18, 2025 | S | 52,990 | $87.15 | Sale −$4,618,079 | 531,920 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Aug 15, 2025 | Aug 18, 2025 | S | 20,000 | $86.97 | Sale −$1,739,400 | 173,226 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Aug 14, 2025 | Aug 18, 2025 | S | 47,010 | $89.48 | Sale −$4,206,455 | 584,910 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Aug 13, 2025 | Aug 14, 2025 | S | 400 | $88.87 | Sale −$35,548 | 76,474 | Yes | Form 4 |
| Haughey Thomas | Aug 12, 2025 | Aug 14, 2025 | S | 19,341 | $85.93 | Sale −$1,661,972 | 36,521 | No | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Aug 12, 2025 | Aug 14, 2025 | S | 4,975 | $85.71 | Sale −$426,407 | 40,794 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Aug 12, 2025 | Aug 14, 2025 | M | 50,000 | $46.49 | $2,324,500 | 230,863 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Aug 12, 2025 | Aug 14, 2025 | S | 50,000 | $86.07 | Sale −$4,303,500 | 180,863 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Aug 12, 2025 | Aug 14, 2025 | M · derivative | 50,000 | $46.49 | $2,324,500 | not reported | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Aug 12, 2025 | Aug 14, 2025 | S | 56,960 | $85.93 | Sale −$4,894,573 | 411,219 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Aug 12, 2025 | Aug 14, 2025 | S | 5,873 | $86.53 | Sale −$508,191 | 84,024 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jul 18, 2025 | Jul 21, 2025 | F | 2,071 | $66.30 | $137,307 | 76,874 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jul 14, 2025 | Jul 14, 2025 | S | 400 | $64.88 | Sale −$25,952 | 78,945 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jun 13, 2025 | Jun 16, 2025 | S | 400 | $61.37 | Sale −$24,548 | 79,345 | Yes | Form 4 |
| Haughey Thomas | May 22, 2025 | May 27, 2025 | A | 4,336 | $0.00 | $0 | 55,862 | No | Form 4 |
| Tannenbaum Renee P | May 22, 2025 | May 27, 2025 | A | 4,336 | $0.00 | $0 | 26,957 | No | Form 4 |
| Pera Antonio R | May 22, 2025 | May 27, 2025 | A | 4,336 | $0.00 | $0 | 35,373 | No | Form 4 |
| Walsh Patrick D | May 22, 2025 | May 27, 2025 | A | 4,336 | $0.00 | $0 | 79,048 | No | Form 4 |
| Leonard Matthew J | May 22, 2025 | May 27, 2025 | A | 4,336 | $0.00 | $0 | 16,329 | No | Form 4 |
| Thoma Jeanne | May 22, 2025 | May 27, 2025 | A | 4,336 | $0.00 | $0 | 44,945 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | May 15, 2025 | May 16, 2025 | S | 881 | $60.07 | Sale −$52,922 | 89,897 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | May 14, 2025 | May 15, 2025 | S | 4,000 | $60.45 | Sale −$241,800 | 107,317 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | May 13, 2025 | May 13, 2025 | S | 400 | $62.20 | Sale −$24,880 | 79,745 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | May 9, 2025 | May 13, 2025 | S | 700 | $76.83 | Sale −$53,781 | 631,920 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Apr 14, 2025 | Apr 14, 2025 | S | 400 | $68.96 | Sale −$27,584 | 80,145 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 23, 2025 | Mar 25, 2025 | F | 6,210 | $64.26 | $399,055 | 180,863 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Mar 23, 2025 | Mar 25, 2025 | F | 17,455 | $64.26 | $1,121,658 | 468,179 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Mar 19, 2025 | Mar 20, 2025 | S | 1,866 | $65.00 | Sale −$121,290 | 64,659 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Mar 13, 2025 | Mar 14, 2025 | S | 400 | $63.33 | Sale −$25,332 | 80,545 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 7, 2025 | Mar 14, 2025 | F | 5,150 | $60.62 | $312,193 | 187,073 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Mar 7, 2025 | Mar 14, 2025 | F | 17,060 | $60.62 | $1,034,177 | 485,634 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Mar 7, 2025 | Mar 14, 2025 | F | 3,314 | $60.62 | $200,895 | 90,778 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Mar 7, 2025 | Mar 14, 2025 | F | 2,874 | $60.62 | $174,222 | 111,317 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Mar 7, 2025 | Mar 10, 2025 | S | 1,000 | $60.86 | Sale −$60,860 | 66,525 | Yes | Form 4 |
| Gutwerg OriSVP, GENERICS | Mar 5, 2025 | Mar 7, 2025 | M | 300 | $31.49 | $9,447 | 99,476 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Mar 5, 2025 | Mar 7, 2025 | S | 300 | $60.03 | Sale −$18,009 | 99,176 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Mar 5, 2025 | Mar 7, 2025 | S | 5,084 | $60.00 | Sale −$305,040 | 94,092 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Mar 5, 2025 | Mar 7, 2025 | M · derivative | 300 | $31.49 | $9,447 | 13,204 | No | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Feb 28, 2025 | Mar 4, 2025 | F | 627 | $61.89 | $38,805 | 45,465 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 28, 2025 | Mar 4, 2025 | F | 1,861 | $61.89 | $115,177 | 192,223 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 28, 2025 | Mar 4, 2025 | F | 12,216 | $61.89 | $756,048 | 502,694 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 28, 2025 | Mar 4, 2025 | F | 1,570 | $61.89 | $97,167 | 99,176 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 28, 2025 | Mar 4, 2025 | F | 1,275 | $61.89 | $78,910 | 114,191 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 28, 2025 | Mar 4, 2025 | F | 1,099 | $61.89 | $68,017 | 80,945 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 28, 2025 | Mar 4, 2025 | F | 1,099 | $61.89 | $68,017 | 67,525 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 21, 2025 | Feb 24, 2025 | S | 1,000 | $60.20 | Sale −$60,200 | 68,624 | Yes | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 15, 2025 | Feb 18, 2025 | F | 1,167 | $58.92 | $68,760 | 100,746 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 15, 2025 | Feb 18, 2025 | F | 1,184 | $58.92 | $69,761 | 115,466 | No | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Feb 14, 2025 | Feb 18, 2025 | F | 582 | $58.92 | $34,291 | 46,092 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 14, 2025 | Feb 18, 2025 | F | 1,730 | $58.92 | $101,932 | 194,084 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 14, 2025 | Feb 18, 2025 | F | 7,799 | $58.92 | $459,517 | 514,910 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 14, 2025 | Feb 18, 2025 | F | 1,426 | $58.92 | $84,020 | 101,913 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 14, 2025 | Feb 18, 2025 | F | 1,473 | $58.92 | $86,789 | 116,650 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 14, 2025 | Feb 18, 2025 | F | 1,434 | $58.92 | $84,491 | 82,044 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 14, 2025 | Feb 18, 2025 | F | 1,196 | $58.92 | $70,468 | 69,624 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 13, 2025 | Feb 18, 2025 | S | 400 | $59.54 | Sale −$23,816 | 83,478 | Yes | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Feb 12, 2025 | Feb 18, 2025 | A | 7,834 | $0.00 | $0 | 41,452 | No | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Feb 12, 2025 | Feb 18, 2025 | A | 5,222 | $0.00 | $0 | 46,674 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 12, 2025 | Feb 18, 2025 | A | 24,808 | $0.00 | $0 | 179,276 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 12, 2025 | Feb 18, 2025 | A | 16,538 | $0.00 | $0 | 195,814 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 12, 2025 | Feb 18, 2025 | A | 91,399 | $0.00 | $0 | 461,777 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 12, 2025 | Feb 18, 2025 | A | 60,932 | $0.00 | $0 | 522,709 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 12, 2025 | Feb 18, 2025 | A | 15,668 | $0.00 | $0 | 92,895 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 12, 2025 | Feb 18, 2025 | A | 10,444 | $0.00 | $0 | 103,339 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 12, 2025 | Feb 18, 2025 | A | 24,808 | $0.00 | $0 | 101,585 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 12, 2025 | Feb 18, 2025 | A | 16,538 | $0.00 | $0 | 118,123 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Feb 12, 2025 | Feb 18, 2025 | A | 14,362 | $0.00 | $0 | 83,014 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Feb 12, 2025 | Feb 18, 2025 | A | 9,574 | $0.00 | $0 | 92,588 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 12, 2025 | Feb 18, 2025 | A | 14,362 | $0.00 | $0 | 64,041 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 12, 2025 | Feb 18, 2025 | A | 9,574 | $0.00 | $0 | 73,615 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 12, 2025 | Feb 18, 2025 | A | 16,974 | $0.00 | $0 | 72,562 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 12, 2025 | Feb 18, 2025 | A | 11,316 | $0.00 | $0 | 83,878 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 12, 2025 | Feb 18, 2025 | A | 13,057 | $0.00 | $0 | 62,116 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 12, 2025 | Feb 18, 2025 | A | 8,704 | $0.00 | $0 | 70,820 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jan 13, 2025 | Jan 13, 2025 | S | 400 | $53.92 | Sale −$21,568 | 55,588 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Dec 17, 2024 | Dec 18, 2024 | S | 7,500 | $55.79 | Sale −$418,425 | 154,468 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Dec 13, 2024 | Dec 16, 2024 | S | 250 | $56.24 | Sale −$14,060 | 55,988 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Dec 11, 2024 | Dec 12, 2024 | S | 1,000 | $60.00 | Sale −$60,000 | 49,059 | Yes | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Nov 26, 2024 | Nov 27, 2024 | M | 30,000 | $29.00 | $870,000 | 403,859 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Nov 26, 2024 | Nov 27, 2024 | S | 30,000 | $57.95 | Sale −$1,738,500 | 373,859 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Nov 26, 2024 | Nov 27, 2024 | S | 3,481 | $58.30 | Sale −$202,942 | 370,378 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Nov 26, 2024 | Nov 27, 2024 | M · derivative | 30,000 | $29.00 | $870,000 | 138,027 | No | Form 4 |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Nov 15, 2024 | Nov 18, 2024 | F | 867 | $56.58 | $49,055 | 33,169 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Nov 15, 2024 | Nov 18, 2024 | S | 6,500 | $57.70 | Sale −$375,050 | 76,777 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Nov 13, 2024 | Nov 14, 2024 | S | 250 | $61.36 | Sale −$15,340 | 56,238 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Oct 14, 2024 | Oct 15, 2024 | S | 250 | $57.19 | Sale −$14,298 | 56,488 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sep 13, 2024 | Sep 16, 2024 | S | 250 | $56.82 | Sale −$14,205 | 56,738 | Yes | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Sep 12, 2024 | Sep 13, 2024 | F | 1,486 | $56.15 | $83,439 | 50,059 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Sep 8, 2024 | Sep 10, 2024 | F | 3,646 | $60.51 | $220,619 | 373,859 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Aug 13, 2024 | Aug 14, 2024 | S | 250 | $59.62 | Sale −$14,905 | 56,988 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jul 18, 2024 | Jul 19, 2024 | S | 2,743 | $62.00 | Sale −$170,066 | 632,620 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jul 18, 2024 | Jul 19, 2024 | F | 1,743 | $61.35 | $106,933 | 57,238 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jul 17, 2024 | Jul 17, 2024 | S | 14,257 | $63.16 | Sale −$900,472 | 635,363 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jul 16, 2024 | Jul 17, 2024 | S | 22,000 | $64.27 | Sale −$1,413,940 | 649,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jul 15, 2024 | Jul 17, 2024 | S | 11,000 | $63.38 | Sale −$697,180 | 671,620 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jul 12, 2024 | Jul 15, 2024 | S | 250 | $64.91 | Sale −$16,228 | 58,981 | Yes | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Jul 1, 2024 | Jul 2, 2024 | S | 20,000 | $63.44 | Sale −$1,268,800 | 193,226 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jun 21, 2024 | Jun 24, 2024 | S | 20,000 | $58.90 | Sale −$1,178,000 | 682,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jun 20, 2024 | Jun 20, 2024 | S | 11,447 | $59.86 | Sale −$685,217 | 702,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jun 18, 2024 | Jun 20, 2024 | S | 10,607 | $60.76 | Sale −$644,481 | 714,067 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jun 17, 2024 | Jun 20, 2024 | S | 7,946 | $61.41 | Sale −$487,964 | 724,674 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jun 13, 2024 | Jun 14, 2024 | S | 250 | $63.80 | Sale −$15,950 | 59,231 | Yes | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Jun 7, 2024 | Jun 11, 2024 | M | 7,250 | $49.51 | $358,948 | 123,616 | No | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Jun 7, 2024 | Jun 11, 2024 | M | 5,300 | $57.06 | $302,418 | 128,916 | No | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Jun 7, 2024 | Jun 11, 2024 | F | 11,087 | $67.70 | $750,590 | 117,829 | No | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Jun 7, 2024 | Jun 11, 2024 | M · derivative | 7,250 | $49.51 | $358,948 | not reported | No | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Jun 7, 2024 | Jun 11, 2024 | M · derivative | 5,300 | $57.06 | $302,418 | not reported | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Jun 5, 2024 | Jun 6, 2024 | S | 2,985 | $67.00 | Sale −$199,995 | 77,227 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Jun 4, 2024 | Jun 6, 2024 | S | 5,000 | $63.58 | Sale −$317,900 | 161,968 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Jun 3, 2024 | Jun 4, 2024 | S | 20,000 | $64.41 | Sale −$1,288,200 | 213,226 | Yes | Form 4 |
| Haughey Thomas | May 21, 2024 | May 23, 2024 | A | 4,410 | $0.00 | $0 | 51,526 | No | Form 4 |
| Tannenbaum Renee P | May 21, 2024 | May 23, 2024 | A | 4,410 | $0.00 | $0 | 22,621 | No | Form 4 |
| Pera Antonio R | May 21, 2024 | May 23, 2024 | A | 4,410 | $0.00 | $0 | 31,037 | No | Form 4 |
| Walsh Patrick D | May 21, 2024 | May 23, 2024 | A | 4,410 | $0.00 | $0 | 74,712 | No | Form 4 |
| Leonard Matthew J | May 21, 2024 | May 23, 2024 | A | 4,410 | $0.00 | $0 | 11,993 | No | Form 4 |
| Thoma Jeanne | May 21, 2024 | May 23, 2024 | A | 4,410 | $0.00 | $0 | 40,609 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | May 21, 2024 | May 22, 2024 | S | 2,000 | $61.61 | Sale −$123,220 | 83,277 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | May 20, 2024 | May 21, 2024 | S | 12,855 | $61.81 | Sale −$794,568 | 732,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | May 17, 2024 | May 17, 2024 | S | 5,836 | $62.09 | Sale −$362,357 | 745,475 | Yes | Form 4 |
| Tannenbaum Renee P | May 16, 2024 | May 17, 2024 | S | 2,000 | $63.87 | Sale −$127,740 | 18,211 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | May 16, 2024 | May 17, 2024 | S | 16,459 | $63.84 | Sale −$1,050,743 | 751,311 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | May 15, 2024 | May 17, 2024 | S | 14,850 | $65.86 | Sale −$978,021 | 767,770 | Yes | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | May 14, 2024 | May 16, 2024 | S | 16,669 | $66.10 | Sale −$1,101,821 | 377,505 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | May 13, 2024 | May 13, 2024 | S | 250 | $67.69 | Sale −$16,923 | 59,481 | Yes | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | May 1, 2024 | May 3, 2024 | S | 20,000 | $66.62 | Sale −$1,332,400 | 233,226 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Apr 19, 2024 | Apr 22, 2024 | S | 16,809 | $65.17 | Sale −$1,095,443 | 782,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Apr 18, 2024 | Apr 22, 2024 | S | 10,423 | $64.98 | Sale −$677,287 | 799,429 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Apr 17, 2024 | Apr 17, 2024 | S | 9,520 | $65.40 | Sale −$622,608 | 809,852 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Apr 16, 2024 | Apr 17, 2024 | S | 5,834 | $66.20 | Sale −$386,211 | 819,372 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Apr 15, 2024 | Apr 17, 2024 | S | 7,414 | $66.33 | Sale −$491,771 | 825,206 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Apr 12, 2024 | Apr 15, 2024 | S | 250 | $67.79 | Sale −$16,948 | 59,731 | Yes | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Apr 10, 2024 | Apr 11, 2024 | F | 2,799 | $66.96 | $187,421 | 116,006 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Apr 10, 2024 | Apr 11, 2024 | F | 4,534 | $66.96 | $303,597 | 166,968 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Apr 1, 2024 | Apr 2, 2024 | S | 20,000 | $67.25 | Sale −$1,345,000 | 253,226 | Yes | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Mar 23, 2024 | Mar 25, 2024 | F | 3,653 | $69.58 | $254,176 | 118,805 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 23, 2024 | Mar 25, 2024 | F | 6,210 | $69.58 | $432,092 | 171,502 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Mar 23, 2024 | Mar 25, 2024 | F | 17,455 | $69.58 | $1,214,519 | 394,174 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Mar 13, 2024 | Mar 13, 2024 | S | 250 | $66.54 | Sale −$16,635 | 59,981 | Yes | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Mar 11, 2024 | Mar 13, 2024 | S | 20,000 | $65.81 | Sale −$1,316,200 | 273,226 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 11, 2024 | Mar 11, 2024 | S | 7,787 | $65.55 | Sale −$510,438 | 177,712 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Mar 8, 2024 | Mar 11, 2024 | S | 10,000 | $67.17 | Sale −$671,700 | 832,620 | Yes | Form 4 |
| Carey Stephen P.SVP & CFO | Mar 7, 2024 | Mar 11, 2024 | F | 4,216 | $66.71 | $281,249 | 185,499 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Mar 8, 2024 | Mar 8, 2024 | S | 16,292 | $67.13 | Sale −$1,093,682 | 411,629 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Mar 7, 2024 | Mar 8, 2024 | F | 17,060 | $66.71 | $1,138,073 | 427,921 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Mar 6, 2024 | Mar 8, 2024 | S | 28,965 | $65.52 | Sale −$1,897,787 | 444,981 | No | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Mar 7, 2024 | Mar 7, 2024 | S | 24,338 | $66.37 | Sale −$1,615,313 | 124,492 | No | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Mar 7, 2024 | Mar 7, 2024 | F | 2,034 | $66.71 | $135,688 | 122,458 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Mar 7, 2024 | Mar 7, 2024 | F | 2,494 | $66.71 | $166,375 | 80,212 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Mar 7, 2024 | Mar 7, 2024 | F | 2,110 | $66.71 | $140,758 | 85,277 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Mar 7, 2024 | Mar 7, 2024 | S | 15,085 | $66.35 | Sale −$1,000,890 | 842,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Mar 6, 2024 | Mar 7, 2024 | S | 14,822 | $65.47 | Sale −$970,396 | 857,705 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Mar 5, 2024 | Mar 7, 2024 | S | 10,093 | $65.35 | Sale −$659,578 | 872,527 | Yes | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Mar 5, 2024 | Mar 6, 2024 | S | 5,000 | $66.00 | Sale −$330,000 | 87,387 | No | Form 4 |
| Pera Antonio R | Mar 4, 2024 | Mar 6, 2024 | S | 7,000 | $65.20 | Sale −$456,400 | 26,627 | No | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Feb 29, 2024 | Mar 1, 2024 | F | 1,058 | $67.67 | $71,595 | 148,830 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 29, 2024 | Mar 1, 2024 | F | 1,914 | $67.67 | $129,520 | 189,715 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 29, 2024 | Mar 1, 2024 | F | 10,014 | $67.67 | $677,647 | 473,946 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 29, 2024 | Mar 1, 2024 | F | 1,570 | $67.67 | $106,242 | 82,706 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 29, 2024 | Mar 1, 2024 | F | 1,275 | $67.67 | $86,279 | 92,387 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Feb 29, 2024 | Mar 1, 2024 | F | 1,122 | $67.67 | $75,926 | 68,652 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 29, 2024 | Mar 1, 2024 | F | 1,635 | $67.67 | $110,640 | 49,679 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 29, 2024 | Mar 1, 2024 | F | 1,173 | $67.67 | $79,377 | 60,231 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 29, 2024 | Mar 1, 2024 | F | 1,173 | $67.67 | $79,377 | 51,545 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 15, 2024 | Feb 20, 2024 | F | 1,244 | $57.55 | $71,592 | 84,276 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 15, 2024 | Feb 20, 2024 | F | 1,261 | $57.55 | $72,571 | 93,662 | No | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Feb 14, 2024 | Feb 16, 2024 | A | 10,066 | $0.00 | $0 | 143,178 | No | Form 4 |
| Marken James G.SVP OPS & PROD DEV | Feb 14, 2024 | Feb 16, 2024 | A | 6,710 | $0.00 | $0 | 149,888 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 14, 2024 | Feb 16, 2024 | A | 21,474 | $0.00 | $0 | 177,313 | No | Form 4 |
| Carey Stephen P.SVP & CFO | Feb 14, 2024 | Feb 16, 2024 | A | 14,316 | $0.00 | $0 | 191,629 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 14, 2024 | Feb 16, 2024 | A | 80,530 | $0.00 | $0 | 430,274 | No | Form 4 |
| Lalwani NikhilPRESIDENT & CEO | Feb 14, 2024 | Feb 16, 2024 | A | 53,686 | $0.00 | $0 | 483,960 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 14, 2024 | Feb 16, 2024 | A | 14,763 | $0.00 | $0 | 75,678 | No | Form 4 |
| Gutwerg OriSVP, GENERICS | Feb 14, 2024 | Feb 16, 2024 | A | 9,842 | $0.00 | $0 | 85,520 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 14, 2024 | Feb 16, 2024 | A | 18,790 | $0.00 | $0 | 82,397 | No | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Feb 14, 2024 | Feb 16, 2024 | A | 12,526 | $0.00 | $0 | 94,923 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Feb 14, 2024 | Feb 16, 2024 | A | 13,421 | $0.00 | $0 | 60,828 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Feb 14, 2024 | Feb 16, 2024 | A | 8,946 | $0.00 | $0 | 69,774 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 14, 2024 | Feb 16, 2024 | A | 13,421 | $0.00 | $0 | 42,368 | No | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Feb 14, 2024 | Feb 16, 2024 | A | 8,946 | $0.00 | $0 | 51,314 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 14, 2024 | Feb 16, 2024 | A | 14,763 | $0.00 | $0 | 51,562 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 14, 2024 | Feb 16, 2024 | A | 9,842 | $0.00 | $0 | 61,404 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 14, 2024 | Feb 16, 2024 | A | 12,079 | $0.00 | $0 | 44,666 | No | Form 4 |
| Davis KristaSVP, CHIEF HR OFFICER | Feb 14, 2024 | Feb 16, 2024 | A | 8,052 | $0.00 | $0 | 52,718 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Feb 13, 2024 | Feb 13, 2024 | S | 250 | $56.04 | Sale −$14,010 | 36,799 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jan 23, 2024 | Jan 23, 2024 | S | 15,000 | $56.44 | Sale −$846,600 | 882,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jan 22, 2024 | Jan 23, 2024 | S | 5,692 | $55.95 | Sale −$318,467 | 897,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jan 19, 2024 | Jan 23, 2024 | S | 4,524 | $55.57 | Sale −$251,399 | 903,312 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jan 18, 2024 | Jan 18, 2024 | S | 9,784 | $55.30 | Sale −$541,055 | 907,836 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jan 17, 2024 | Jan 18, 2024 | S | 10,000 | $55.11 | Sale −$551,100 | 917,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Jan 16, 2024 | Jan 18, 2024 | S | 5,000 | $55.63 | Sale −$278,150 | 927,620 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Jan 12, 2024 | Jan 16, 2024 | S | 250 | $56.43 | Sale −$14,108 | 37,049 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Dec 19, 2023 | Dec 19, 2023 | S | 25,000 | $52.65 | Sale −$1,316,250 | 932,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Dec 18, 2023 | Dec 19, 2023 | S | 13,026 | $52.44 | Sale −$683,083 | 957,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Dec 15, 2023 | Dec 19, 2023 | S | 11,974 | $52.44 | Sale −$627,917 | 970,646 | Yes | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Dec 11, 2023 | Dec 11, 2023 | S | 250 | $49.21 | Sale −$12,303 | 37,299 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Nov 17, 2023 | Nov 20, 2023 | S | 13,000 | $51.00 | Sale −$663,000 | 982,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Nov 16, 2023 | Nov 20, 20234/A | S | 6,448 | $51.66 | Sale −$333,104 | 995,620 | Yes | Form 4/A |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Nov 15, 2023 | Nov 20, 20234/A | S | 7,647 | $53.64 | Sale −$410,185 | 1,002,068 | Yes | Form 4/A |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Nov 14, 2023 | Nov 20, 20234/A | S | 22,905 | $53.17 | Sale −$1,217,859 | 1,009,715 | Yes | Form 4/A |
| Davis KristaSVP, CHIEF HR OFFICER | Nov 15, 2023 | Nov 16, 2023 | S | 2,622 | $53.81 | Sale −$141,090 | 32,587 | No | Form 4 |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Nov 13, 2023 | Nov 14, 2023 | S | 250 | $52.03 | Sale −$13,008 | 37,549 | Yes | Form 4 |
| Mutz ChristopherHEAD OF RARE DISEASE | Nov 10, 2023 | Nov 13, 2023 | S | 3,000 | $52.47 | Sale −$157,410 | 63,607 | No | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Oct 19, 2023 | Oct 19, 2023 | S | 10,000 | $57.06 | Sale −$570,600 | 1,032,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Oct 18, 2023 | Oct 19, 2023 | S | 6,242 | $57.78 | Sale −$360,663 | 1,042,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Oct 17, 2023 | Oct 19, 2023 | S | 8,758 | $58.53 | Sale −$512,606 | 1,048,862 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Oct 16, 2023 | Oct 17, 2023 | S | 13,063 | $58.31 | Sale −$761,704 | 1,057,620 | Yes | Form 4 |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS | Oct 13, 2023 | Oct 17, 2023 | S | 11,937 | $57.58 | Sale −$687,332 | 1,070,683 | Yes | Form 4 |
| Gassert ChadSVP - CORP. DEV. & STRATEGY | Oct 2, 2023 | Oct 3, 2023 | S | 20,000 | $56.48 | Sale −$1,129,600 | 293,226 | Yes | Form 4 |